Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (13936)	7/3/2000 12:47:18 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

Gw optimism, Blue negativsm, Rk neutralsm, We got all the folks together. Gw, your are really suave, $100M in 3 years of marketing? and you expect it out in 2 years?, the truth is Allergan is a great marketeer, but this is way optimistic. I say 4 years to get to market, and 10 years to global sales (not just US)of $50M. Blue, pseudomonas in some postoperative eye infections, especially the cornea that is poorly vascularized and antibiotics do not reach well, is an example of the kind o lesions one will imagine rbpieyeversion to theoretically be worth the money they will charge, but all those weird bugs from the amazon and congo jungles are no a way to market this Iprex thing. How many anacondas will need iprex after a frog spit on her eyes? A big market could be prevention, Allergan will add bpi to all the contact lens cleaners, and to all the irritated eyes, but it could be that the manufacture plan can produce it for few dollars (those huge margins in Amgn, Dna, Bgen, Medi are not due to expensive manufacturing after all). But, poor blue, he does not like bpi enhanced qualities!!! The best deal will be to add it to Listerine/alcohol free version (to be hated by many, but churches), for sorethroat, this is one of those unmet medical needs, no antibiotic has being able to get patients to feel better, but the baboon king fast bug killer will be. At the time, Blue will be the Chief executioner officer of Amaxoma.org!

To: Bluegreen who wrote (13936)	7/4/2000 6:32:06 PM
From: Robert K.	Respond to of 17367

Ok> what were the paramaterers of the hemo trauma trial? >XOMA has completed the design of and is initiating its Phase III pivotal trial to test Neuprex(tm) as a treatment to prevent infections and infectious complications in patients suffering hemorrhage due to trauma. The primary endpoint will be a reduction in the percentage of patients experiencing severe pulmonary complications, i.e., pneumonia and/or acute respiratory distress syndrome (ARDS). The trial is designed to enroll 1,650 patients who receive two or more units of blood as a result of blunt or penetrating trauma. The company has submitted the protocol to more than 40 prospective study sites for approval prior to starting the trial" Readagain>to enroll 1,650 patients who receive two or more units of blood ncbi.nlm.nih.gov Read again BPI was found in all units of packed red cells tested at concentrations up to 15 times preoperative plasma levels in patients So...... as my theory goes, was there REALLY a placebo grp?